NASDAQ:MIST Milestone Pharmaceuticals (MIST) Stock Price, News & Analysis → Radical change coming — do this NOW to protect yourself (From Weiss Ratings) (Ad) Free MIST Stock Alerts $1.40 -0.01 (-0.71%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$1.39▼$1.4250-Day Range$1.41▼$1.8252-Week Range$1.33▼$3.86Volume60,922 shsAverage Volume270,711 shsMarket Capitalization$74.56 millionP/E RatioN/ADividend YieldN/APrice Target$10.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Milestone Pharmaceuticals alerts: Email Address Milestone Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside667.9% Upside$10.75 Price TargetShort InterestHealthy0.90% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.79) to ($1.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.94 out of 5 starsMedical Sector620th out of 913 stocksPharmaceutical Preparations Industry291st out of 429 stocks 3.4 Analyst's Opinion Consensus RatingMilestone Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMilestone Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Milestone Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.90% of the outstanding shares of Milestone Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMilestone Pharmaceuticals has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Milestone Pharmaceuticals has recently increased by 5.08%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMilestone Pharmaceuticals does not currently pay a dividend.Dividend GrowthMilestone Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MIST. Previous Next 2.7 News and Social Media Coverage News SentimentMilestone Pharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Milestone Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Milestone Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.40% of the stock of Milestone Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.18% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Milestone Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Milestone Pharmaceuticals are expected to decrease in the coming year, from ($0.79) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Milestone Pharmaceuticals is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Milestone Pharmaceuticals is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMilestone Pharmaceuticals has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Milestone Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading Academyonly trade options on these 5-7 stocksI'm going to reveal the only 5-7 stocks you should be trading. But here's the secret - there's nothing special about these stocks. What matters is the repeatable options trading system I use to trade them.Click here to download my options trading cheat sheet (5-7 stocks inside here) About Milestone Pharmaceuticals Stock (NASDAQ:MIST)Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Read More MIST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MIST Stock News HeadlinesJune 12, 2024 | globenewswire.comMilestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024May 31, 2024 | globenewswire.comMilestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare ConferenceMay 29, 2024 | finanznachrichten.deMilestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYSTMay 29, 2024 | globenewswire.comMilestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™May 22, 2024 | finance.yahoo.comMilestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT AwarenessMay 16, 2024 | markets.businessinsider.comMilestone Pharmaceuticals Upgraded to Buy: Here's What You Should KnowMay 16, 2024 | markets.businessinsider.comMilestone Pharmaceuticals’ Strong Buy Rating: CARDAMYST’s FDA Resubmission and Bright Revenue ProspectsMay 14, 2024 | morningstar.comMilestone Pharmaceuticals Inc MISTMay 13, 2024 | washingtonpost.comMilestone Pharmaceuticals: Q1 Earnings SnapshotMay 13, 2024 | globenewswire.comMilestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate UpdateMay 2, 2024 | finance.yahoo.comMilestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024April 17, 2024 | finance.yahoo.comMilestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing SymposiumApril 17, 2024 | globenewswire.comMilestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing SymposiumApril 8, 2024 | finance.yahoo.comMilestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual MeetingApril 8, 2024 | globenewswire.comMilestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual MeetingApril 3, 2024 | finance.yahoo.comMilestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare ConferenceApril 1, 2024 | globenewswire.comMilestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual ConferencesMarch 28, 2024 | finance.yahoo.comMilestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular TachycardiaMarch 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Milestone Pharmaceuticals (MIST)March 21, 2024 | markets.businessinsider.comMilestone Pharmaceuticals’ Etripamil Nears Approval: A Strong Buy RecommendationMarch 21, 2024 | investorplace.comMIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023March 21, 2024 | globenewswire.comMilestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate UpdateFebruary 29, 2024 | globenewswire.comMilestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care ConferenceFebruary 29, 2024 | globenewswire.comMilestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded WarrantsFebruary 28, 2024 | marketwatch.comMilestone Pharma Shares Drop After Public Offering NewsSee More Headlines Receive MIST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/17/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MIST CUSIPN/A CIK1408443 Webwww.milestonepharma.com Phone(514) 336-0444FaxN/AEmployees47Year FoundedN/APrice Target and Rating Average Stock Price Target$10.75 High Stock Price Target$25.00 Low Stock Price Target$4.00 Potential Upside/Downside+673.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,690,000.00 Net MarginsN/A Pretax Margin-5,968.50% Return on Equity-175.44% Return on Assets-62.01% Debt Debt-to-Equity Ratio1.27 Current Ratio22.75 Quick Ratio22.75 Sales & Book Value Annual Sales$1 million Price / Sales74.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book2.78Miscellaneous Outstanding Shares53,260,000Free Float47,721,000Market Cap$74.03 million OptionableOptionable Beta1.73 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Joseph G. Oliveto M.B.A. (Age 56)CEO, President & Director Comp: $949.47kMr. Amit Hasija (Age 51)CFO & Executive VP of Corporate Development Comp: $634.89kDr. David B. Bharucha FACC (Age 62)M.D., Ph.D., Chief Medical Officer Comp: $691.43kDr. Philippe Douville M.B.A. (Age 62)Ph.D., Founder, Strategic Advisor & Member of Scientific Advisory Board Mr. Jeffrey Nelson (Age 43)Chief Operating Officer Ms. Kim FoxVice President of CommunicationsDr. Philip T. Sager FACC (Age 68)FAHA, FHRS, M.D., Chief Medical Advisor & Member of the Scientific Advisory Board Dr. Guy RousseauSVP of Regulatory Affairs and Quality ManagementMs. Anita HolzVP & Head of Medical AffairsMore ExecutivesKey CompetitorsStrongbridge BiopharmaNASDAQ:SBBPVeruNASDAQ:VERUKamadaNASDAQ:KMDAInozyme PharmaNASDAQ:INZYSkye BioscienceNASDAQ:SKYEView All CompetitorsInstitutional OwnershipBNP Paribas Financial MarketsBought 10,800 shares on 5/1/2024Ownership: 0.032%Clear Creek Financial Management LLCSold 6,750 shares on 4/26/2024Ownership: 0.047%BML Capital Management LLCBought 163,793 shares on 4/23/2024Ownership: 1.140%View All Institutional Transactions MIST Stock Analysis - Frequently Asked Questions Should I buy or sell Milestone Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MIST shares. View MIST analyst ratings or view top-rated stocks. What is Milestone Pharmaceuticals' stock price target for 2024? 4 equities research analysts have issued 1 year price objectives for Milestone Pharmaceuticals' stock. Their MIST share price targets range from $4.00 to $25.00. On average, they predict the company's share price to reach $10.75 in the next twelve months. This suggests a possible upside of 667.9% from the stock's current price. View analysts price targets for MIST or view top-rated stocks among Wall Street analysts. How have MIST shares performed in 2024? Milestone Pharmaceuticals' stock was trading at $1.67 on January 1st, 2024. Since then, MIST shares have decreased by 16.2% and is now trading at $1.40. View the best growth stocks for 2024 here. When is Milestone Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our MIST earnings forecast. How were Milestone Pharmaceuticals' earnings last quarter? Milestone Pharmaceuticals Inc. (NASDAQ:MIST) released its quarterly earnings data on Monday, May, 13th. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.05. What other stocks do shareholders of Milestone Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), iBio (IBIO), Allena Pharmaceuticals (ALNA), Fulcrum Therapeutics (FULC), OPKO Health (OPK), VYNE Therapeutics (VYNE), Soleno Therapeutics (SLNO) and Agile Therapeutics (AGRX). When did Milestone Pharmaceuticals IPO? Milestone Pharmaceuticals (MIST) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray served as the underwriters for the IPO and Oppenheimer & Co. was co-manager. Who are Milestone Pharmaceuticals' major shareholders? Milestone Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BML Capital Management LLC (1.14%), Clear Creek Financial Management LLC (0.05%) and BNP Paribas Financial Markets (0.03%). Insiders that own company stock include David Bharucha, Debra K Liebert, Paul F Truex, Robert James Wills and Rtw Investments, Lp. View institutional ownership trends. How do I buy shares of Milestone Pharmaceuticals? Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MIST) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | Sponsoredonly trade options on these 5-7 stocksI'm going to reveal the only 5-7 stocks you should be trading. But here's the secret - there's nothing spec...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does ...Porter & Company | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
